Michigan Initial Experience Using Tigertriever for Thrombectomy (MIGHTY)

May 6, 2026 updated by: Alex Chebl, Henry Ford Health System
The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

You have been asked to take part in a research study because you have recently been admitted for large vessel occlusion (LVO) and are being treated by Tigertriever.

The treatment is a standard of care (SOC), and if you agree to take part in this study, your participation will include an additional study visit after 3 months. Your study visit will take place at Henry Ford Hospital Neurology or respective collaborator.

For some research studies, such as the one you are being asked to join, it is important that you do not learn the results of certain tests. Whether you intend it or not, sometimes learning this information may make you change your actions and behaviors in ways that could impact the outcome of the study.

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The registry will include male or female subjects age > 18 who present with LVO and are treated with the Tigertriever as per the approved indication.

Description

Inclusion Criteria:

  1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.
  2. Tigertriever was used as the first line treatment in the target vessel.
  3. A signed informed consent.
  4. Age ≥ 18.

Exclusion Criteria:

-1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.

3. pre-stroke disability (pre-stroke mRS ≥ 2).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Thrombectomy Treated Patients
Patients are enrolled only if the use of the Tigertreiver is used during surgery.
Procedure: Mechanical Thrombectomy
You will be asked to provide medical history, take neurological exams in the form of questionnaires, and provide imaging data.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Rankin Scale
Time Frame: From enrollment to 90 days post treatment
Percentage of participants with a modified Rankin Scale (mRS) score ≤2
From enrollment to 90 days post treatment
Primary Effectiveness Endpoint
Time Frame: By the end of the thrombectomy procdure.
Percentage of participants with a mTICI Score ≥IIb
By the end of the thrombectomy procdure.
Primary Effectiveness Endpoint - mTICI
Time Frame: From time of event to after the first thrombectomy pass.
Percentage of participants with a mTICI Score ≥IIb after the first pass
From time of event to after the first thrombectomy pass.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Henry Ford Health System

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

January 8, 2026

First Submitted That Met QC Criteria

January 14, 2026

First Posted (Actual)

January 23, 2026

Study Record Updates

Last Update Posted (Actual)

May 8, 2026

Last Update Submitted That Met QC Criteria

May 6, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 18750

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

De-identified data will only be shared and used for publication.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe